Organon R&D Head Sandra Milligan to depart Jan 5; ceased role Dec 1

Organon & Co.

Dr. Sandra Milligan, Head of Research and Development, will leave Organon on January 5, 2024.
She ceased performing her R&D functions effective December 1, 2023, and will serve as a senior advisor until her departure.
No replacement has been announced for the R&D leadership role.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Dr. Sandra Milligan

Head of Research and Development

OGN · Organon & Co.

Effective: 2024-01-05
Filed: December 5, 2023, 6:59 PM ET

On December 5, 2023, Organon & Co. (the “ Company ”) announced that Dr. Sandra Milligan will be departing from the Company on January 5, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Sandra Milligan departed as Head of Research and Development at Organon & Co..

Action: departing
Role: Head of Research and Development

Exact text from the filing

On December 5, 2023, Organon & Co. (the “ Company ”) announced that Dr. Sandra Milligan will be departing from the Company on January 5, 2024.

View on SEC.gov

Organon & Co. filing history →

Source: SEC EDGAR

accession 0001104659-23-123628

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.